BioSpace News Archive

Florida Blue providing Lyft ridesharing services to its ACA members

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today issued the following letter that it intends to mail to shareholders, urging shareholders to revoke any consents previously delivered to Velan Capital L.P. (“Velan”) by signing and returning Progenics’ WHITE Consent Revocation Card.

DermaVita has obtained an EUIPO finding in its favor following US pharmaceutical company Abbvie’s announcement on 25/06/2019 of its acquisition of Allergan.

At Solidarity HealthShare, we facilitate our members’ healthcare costs and negotiate transparent, reasonable pricing, on average saving 60%, allowing members to can keep their doctors

PurpleStride Supports the Pancreatic Cancer Action Network’s Urgent Mission to Save Lives and Double Pancreatic Cancer Survival

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on October 30, 2019, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 81,000 shares of its common stock to 61 new employees under Xeris’ Inducement Equity Plan.

Titan Medical Inc. is pleased to announce that it has filed and been receipted for a final short form prospectus in connection with the previously announced marketed offering of units of the Company at a price of US $0.45 per Unit for minimum gross proceeds of US $15,000,000 and maximum gross proceeds of US $25,000,000.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN, the “Company”), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today reported financial results for the quarter ended September 30, 2019, and provided a review of recent accomplishments and anticipated milestones.

Portola Pharmaceuticals, Inc.® announced that on October 31, 2019, the Compensation Committee of the Board of Directors approved, effective as of October 31, 2019, the grant to six new employees of inducement stock options to purchase an aggregate of 137,700 shares of common stock, and awards of 66,350 restricted stock units in the aggregate.

Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology, today announced that a paper published in the Journal of Clinical Respiratory Diseases and Care, titled “Assessing the Clinical Effect of High Velocity Nasal Insufflation on Improving Ambulation in Patients with Dyspnea: A Feasibility Study”